TVANIO-DAC (CJC-1295 DAC) 2 mg x 5 Vials – Denik Pharm

Description

Denik Pharm TVANIO-DAC (CJC-1295 DAC) 2 mg is a premium research peptide formulated with CJC-1295 with Drug Affinity Complex (DAC), a long-acting analogue of Growth Hormone Releasing Hormone (GHRH) engineered to provide prolonged biological activity for advanced endocrine and peptide research. By incorporating the Drug Affinity Complex (DAC), this modified peptide exhibits an extended duration of action, making it an essential research tool for scientists investigating sustained hormone signaling, endocrine regulation, and growth factor physiology.

Unlike short-acting GHRH analogues, CJC-1295 DAC is designed to remain biologically active for significantly longer periods, allowing researchers to study the effects of continuous GHRH receptor activation and prolonged downstream IGF-1 signaling. Its unique pharmacokinetic profile has made it one of the most extensively researched peptides in molecular endocrinology, peptide pharmacology, and growth hormone biology.

Each package contains 5 lyophilized vials, with 2 mg of CJC-1295 DAC per vial, delivering a high-purity research formulation manufactured by Denik Pharm under strict pharmaceutical-quality standards to ensure exceptional purity, molecular stability, and batch-to-batch consistency.

Key Features

• Premium CJC-1295 DAC (Drug Affinity Complex) research peptide
• 2 mg of high-purity peptide per vial
• 5 lyophilized vials per pack
• Long-acting analogue of Growth Hormone Releasing Hormone (GHRH)
• Drug Affinity Complex (DAC) technology for prolonged biological activity
• High-purity laboratory-grade formulation
• Extensively researched in endocrine physiology and growth factor biology
• Suitable for investigations involving GHRH receptor activation, sustained hormone signaling, IGF-1 regulation, and peptide pharmacology
• Manufactured under rigorous pharmaceutical-quality standards
• Intended exclusively for laboratory and scientific research applications

How It Works

CJC-1295 DAC selectively binds to Growth Hormone Releasing Hormone (GHRH) receptors within the anterior pituitary, initiating intracellular signaling pathways responsible for regulating endogenous growth hormone secretion. The addition of the Drug Affinity Complex (DAC) allows the peptide to bind to circulating albumin, significantly extending its biological presence and enabling researchers to investigate prolonged receptor stimulation and sustained endocrine responses.

In laboratory settings, TVANIO-DAC is widely used to study long-term GHRH receptor signaling, endocrine feedback mechanisms, IGF-1 production, and the molecular pathways involved in cellular metabolism and growth factor regulation. Researchers also compare its pharmacodynamic characteristics with CJC-1295 NON-DAC (Modified GRF 1-29) to better understand the influence of peptide half-life on hormone pulsatility, receptor sensitivity, and endocrine communication.

This formulation is intended exclusively for laboratory and scientific research and is not intended for human consumption.

Contents

Active Ingredient: CJC-1295 DAC (Drug Affinity Complex) – 2 mg

Packaging: 5 Lyophilized Vials